Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 03/28/18

Charles Kunos, MD, PhD


Charles Kunos, MD, PhD, Medical Officer

Dr. Charles Kunos joined CTEP in 2016. He received his MD and PhD from Case Western Reserve University School of Medicine. Subsequently, he served as the Clinical Director of the Gynecologic, Pediatric, and Musculoskeletal Radiation Therapy service lines in the Department of Radiation Oncology at University Hospitals of Cleveland and Assistant Professor in the Department of Radiation Oncology at Case Western Reserve University. In this capacity, he was responsible for delivering teletherapy in the clinic and brachytherapy in the clinic and the operating room. He developed skills in helical tomotherapy, gamma knife radiosurgery, and Cyberknife stereotactic body radiosurgery. In addition, he was the Gynecologic Oncology Group liaison for Radiation Medicine, serving on multiple committees, including the Developmental Therapeutics Committee of the NRG Oncology cooperative group, serving as co-chair of the phase I committee between January 2012 and February 2015. He has served on the National Cancer Institute Uterine Task Force since 2012.

Dr. Kunos was responsible for overseeing a preclinical laboratory focused on the science of ribonucleotide reductase, utilizing a NCI-Cancer Therapy Evaluation Program (CTEP)-Case Western Reserve University agreement to conduct preclinical studies of the ribonucleotide reductase inhibitor Triapine in uterine cervix cancer. He subsequently was the principal investigator on NCI-sponsored Phase I and Phase II clinical trials of Triapine radiochemotherapy in uterine cervix cancer patients, which demonstrated high response rates that are being further evaluated in CTEP-sponsored trials.

More recently, he served as the Medical Director of Radiation Oncology at Summa Health (Akron, Ohio) where he treated patients with brachytherapy and stereotactic radiosurgery. He received certification and medical expertise in Vero radiosurgery and Vero dynamic tumor tracking, and radiation safety administration of the Vero platform and led the clinical development of the first Vero radiosurgery program in a community hospital setting in the world.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6939
Fax: 240-276-7894

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in January 2014 after serving part time since August 2012. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…